Taiyun Kim

Taiyun Kim

Auto-generated profile, based on publicly available information

Taiyun Kim

The University of Sydney

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
TKTaiyun Kim
Taiyun Kim
OTOwen Tang
Owen Tang
SVStephen T. Vernon
Stephen T. Vernon
KBKatharine A Bate
Katharine A Bate
Yen Chin KoayYen Chin Koay
Yen Chin Koay
JYJean YH Yang
Jean YH Yang
Liquid chromatography-mass spectrometry-based metabolomics studies are increasingly applied to large population cohorts, which run for several weeks or even years in data acquisition. This inevitably introduces unwanted intra- and inter-batch variations over time that can overshadow true biological signals and thus hinder potential biological discoveries. To date, normalisation approaches have struggled to mitigate the variability introduced by technical factors whilst preserving biological variance, especially for protracted acquisitions. Here, we propose a study design framework with an arrangement for embedding biological sample replicates to quantify variance within and between batches and a workflow that uses these replicates to remove unwanted variation in a hierarchical manner (hRUV). We use this design to produce a dataset of more than 1000 human plasma samples run over an extended period of time. We demonstrate significant improvement of hRUV over existing methods in preserving biological signals whilst removing unwanted variation for large scale metabolomics studies. Our tools not only provide a strategy for large scale data normalisation, but also provides guidance on the design strategy for large omics studies.

22 April 2021 in Cells
Verified
Journal Article
Open access
PDF file
SVStephen Vernon
Stephen Vernon
OTOwen Tang
Owen Tang
TKTaiyun Kim
Taiyun Kim
ACAdam S. Chan
Adam S. Chan
KBKatharine A Bate
Katharine A Bate
Gemma FigtreeGemma Figtree
Gemma Figtree
Despite effective prevention programs targeting cardiovascular risk factors, coronary artery disease (CAD) remains the leading cause of death. Novel biomarkers are needed for improved risk stratification and primary prevention. To assess for independent associations between plasma metabolites and specific CAD plaque phenotypes we performed liquid chromatography mass-spectrometry on plasma from 1002 patients in the BioHEART-CT study. Four metabolites were examined as candidate biomarkers. Dimethylguanidino valerate (DMGV) was associated with presence and amount of CAD (OR) 1.41 (95% Confidence Interval [CI] 1.12–1.79, p = 0.004), calcified plaque, and obstructive CAD (p < 0.05 for both). The association with amount of plaque remained after adjustment for traditional risk factors, ß-coefficient 0.17 (95% CI 0.02–0.32, p = 0.026). Glutamate was associated with the presence of non-calcified plaque, OR 1.48 (95% CI 1.09–2.01, p = 0.011). Phenylalanine was associated with amount of CAD, ß-coefficient 0.33 (95% CI 0.04–0.62, p = 0.025), amount of calcified plaque, (ß-coefficient 0.88, 95% CI 0.23–1.53, p = 0.008), and obstructive CAD, OR 1.84 (95% CI 1.01–3.31, p = 0.046). Trimethylamine N-oxide was negatively associated non-calcified plaque OR 0.72 (95% CI 0.53–0.97, p = 0.029) and the association remained when adjusted for traditional risk factors. In targeted metabolomic analyses including 53 known metabolites and controlling for a 5% false discovery rate, DMGV was strongly associated with the presence of calcified plaque, OR 1.59 (95% CI 1.26–2.01, p = 0.006), obstructive CAD, OR 2.33 (95% CI 1.59–3.43, p = 0.0009), and amount of CAD, ß-coefficient 0.3 (95% CI 0.14–0.45, p = 0.014). In multivariate analyses the lipid and nucleotide metabolic pathways were both associated with the presence of CAD, after adjustment for traditional risk factors. We report novel associations between CAD plaque phenotypes and four metabolites previously associated with CAD. We also identified two metabolic pathways strongly associated with CAD, independent of traditional risk factors. These pathways warrant further investigation at both a biomarker and mechanistic level.

1 June 2021 in STAR Protocols
Verified
Journal Article
Open access
HKHani Jieun Kim
Hani Jieun Kim
TKTaiyun Kim
Taiyun Kim
DXDi Xiao
Di Xiao
PYPengyi Yang
Pengyi Yang
Analysis of phosphoproteomic data requires advanced computational methodologies. To this end, we developed PhosR, a set of tools and methodologies implemented in R to allow the comprehensive analysis of phosphoproteomic data. PhosR enables processing steps such as imputation, normalization, and functional analysis such as kinase activity inference and signalome construction. Together, PhosR facilitates interpretation and discovery from large-scale phosphoproteomic data sets.

22 December 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
TKTaiyun Kim
Taiyun Kim
OTOwen Tang
Owen Tang
SVStephen T Vernon
Stephen T Vernon
KKKatharine A Kott
Katharine A Kott
Yen Chin KoayYen Chin Koay
Yen Chin Koay
JYJean YH Yang
Jean YH Yang
Liquid chromatography-mass spectrometry based metabolomics studies are increasingly applied to large population cohorts, running for several weeks to months, even extending to years of data acquisition. This inevitably introduces unwanted intra- and inter-batch variations over time that can overshadow true biological signals and thus hinder potential biological discoveries. To date, normalization approaches have struggled to mitigate the variability introduced by technical factors whilst preserving biological variance, especially for protracted acquisitions. Here, we designed an experiment with an arrangement to embed biological sample replicates to measure the variance within and between batches for over 1,000 human plasma samples run over 44 days. We integrate these replicates in a novel workflow to remove unwanted variation in a hierarchical structure (hRUV) by progressively merging the adjustments in neighbouring batches. We demonstrate significant improvement of hRUV over existing methods in maintaining biological signals whilst removing unwanted variation for large scale metabolomics studies.

1 September 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
HKHani Jieun Kim
Hani Jieun Kim
TKTaiyun Kim
Taiyun Kim
NHNolan Hoffman
Nolan Hoffman
DXDi Xiao
Di Xiao
DJDavid E James
David E James
PYPengyi Yang
Pengyi Yang
SUMMARY: Mass spectrometry (MS)-based phosphoproteomics has revolutionised our ability to profile phosphorylation-based signalling in cells and tissues on a global scale. To infer the action of kinases and signalling pathways in phosphoproteomic experiments, we present PhosR, a set of tools and methodologies implemented in a suite of R packages facilitating comprehensive analysis of phosphoproteomic data. By applying PhosR to both published and new phosphoproteomic datasets, we demonstrate capabilities in data imputation and normalisation using a novel set of ‘stably phosphorylated sites’, and in functional analysis for inferring active kinases and signalling pathways. In particular, we introduce a ‘signalome’ construction method for identifying a collection of signalling modules to summarise and visualise the interaction of kinases and their collective actions on signal transduction. Together, our data and findings demonstrate the utility of PhosR in processing and generating novel biological knowledge from MS-based phosphoproteomic data.

4 February 2021 in Research Square
Verified
Preprint
Open access
PDF file
TKTaiyun Kim
Taiyun Kim
OTOwen Tang
Owen Tang
SVStephen Vernon
Stephen Vernon
KKKatharine Kott
Katharine Kott
YKYen Chin Koay
Yen Chin Koay
JYJean YH Yang
Jean YH Yang
Liquid chromatography-mass spectrometry-based metabolomics studies are increasingly applied to large population cohorts, which run for several weeks or even years in data acquisition. This inevitably introduces unwanted intra- and inter-batch variations over time that can overshadow true biological signals and thus hinder potential biological discoveries. To date, normalisation approaches have struggled to mitigate the variability introduced by technical factors whilst preserving biological variance, especially for protracted acquisitions. Here, we propose a study design framework with an arrangement for embedding biological sample replicates to quantify variance within and between batches and a novel workflow that uses these replicates to remove unwanted variation in a hierarchical (hRUV) manner. We use this design to produce a dataset of more than 1,000 human plasma samples run over an extended period of time. We demonstrate significant improvement of hRUV over existing methods in preserving biological signals whilst removing unwanted variation for large scale metabolomics studies. Our novel tools not only provide a strategy for large scale data normalization, but also provides guidance on the design strategy for large omics studies.